Inotiv Announces Pricing Of Public Offering Of 6M Common Shares Of Common Stock At A Price Of $4.25/Share
Inotiv Announces Pricing Of Public Offering Of 6M Common Shares Of Common Stock At A Price Of $4.25/Share
Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 900,000 common shares at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on December 19, 2024, subject to customary closing conditions.
Inotiv, Inc.（納斯達克：NOTV）（"公司"）是一家領先的合同研究組織，專注於非臨床和分析藥物發現及開發服務，以及研究模型和相關產品及服務，今天宣佈以每股4.25美元的價格定價其6,000,000股普通股的承銷公開發行。此外，公司已向承銷商授予30天的選擇權，以購買最多額外900,000股普通股，價格爲公開發行價減去承銷折扣和佣金。所有股票均由公司提供。該發行預計將於2024年12月19日完成，須符合慣例的交割條件。
The Company intends to use the net proceeds from this offering for working capital, capital expenditures and other general corporate purposes.
公司計劃將此次發行的淨收益用於營運資金、資本支出和其他一般企業用途。
Lake Street Capital Markets, LLC is acting as the sole book-running manager for the proposed offering.
Lake Street 資本市場公司是擬議發行的唯一賬簿管理人。
譯文內容由第三人軟體翻譯。
